|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-1-19
|
|
pubmed:abstractText |
Recently, chronic supplementation with alpha-galactosidase A (alphaGal A) has been approved as a treatment modality for Fabry disease. The aim of the current study was to investigate the feasibility of home therapy for Fabry disease during a follow-up of >3 years and to make a proposal for practice guidelines.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0931-0509
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
355-60
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16249196-Adolescent,
pubmed-meshheading:16249196-Adult,
pubmed-meshheading:16249196-Aged,
pubmed-meshheading:16249196-Algorithms,
pubmed-meshheading:16249196-Fabry Disease,
pubmed-meshheading:16249196-Feasibility Studies,
pubmed-meshheading:16249196-Female,
pubmed-meshheading:16249196-Follow-Up Studies,
pubmed-meshheading:16249196-Home Care Services,
pubmed-meshheading:16249196-Humans,
pubmed-meshheading:16249196-Isoenzymes,
pubmed-meshheading:16249196-Male,
pubmed-meshheading:16249196-Middle Aged,
pubmed-meshheading:16249196-Netherlands,
pubmed-meshheading:16249196-Practice Guidelines as Topic,
pubmed-meshheading:16249196-Time Factors,
pubmed-meshheading:16249196-alpha-Galactosidase
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands.
|
|
pubmed:affiliation |
Internal Medicine/Clinical Haematology, Academic Medical Centre, Amsterdam, The Netherlands. g.e.linthorst@amc.uva.nl
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
